Generalized Anxiety Disorder (GAD) is a highly prevalent chronic, under-recognized and under-treated psychiatric disorder, causing significant symptomatic and psychosocial impairment. Antidepressants such as imipramine, paroxetine, or venlafaxine XR, and the 5-HT1A partial agonist buspirone are considered presently the preferred treatments for acute and long term treatment. Despite the fact that GAD is a chronic disorder and frequently demands prolonged treatment with medication there is very little known about the benefits of long-term treatment. The efficacy of the SSRIs/SNRI class of medications such as paroxetine and venlafaxine XR is clearly evident in controlled, double-blind trials. However, there are only few studies that assess benefits of more than 8 weeks of treatment and no study for longer than 6 months. Therefore, it is not known for how long medication treatment should be continued to allow maximum symptom relief. In addition, it is unknown if, when,and how quickly symptoms return following a course of long-term medication treatment. This proposal tests, under double-blind conditions, two primary hypotheses. 1) 6 months of treatment with venlafaxine XR, followed by 6 months of placebo will be associated with significantly more relapse and lower levels of remission than treatment with venlafaxine XR for 12 months. 2) Treatment discontinuation after 6 months of venlafaxine XR therapy will be associated with significantly higher relapse rates than treatment discontinuation after 12 months of venlafaxine XR therapy. Following open label treatment with venlafaxine XR for 6 months approximately 165 patients will be available to be randomized into the relapse part of the study. Randomization will be stratified by severity of secondary depressive symptomatology at baseline and level of clinical global improvement obtained after 6 months of venlafaxine XR therapy. This study will allow the examination of relapse rates after 6 and 12 months of venlafaxine XR treatment as a function of improvement status, level of depressive symptoms at baseline, lifetime history of MDD, chronicity of GAD, and length of venlafaxine XR therapy (6 vs. 12 months). The proposed study will provide much needed data, lacking from the literature, about the value of long term medication treatment of patients with a DSM-IV GAD diagnosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH065963-03
Application #
7001240
Study Section
Interventions Research Review Committee (ITV)
Program Officer
Rudorfer, Matthew V
Project Start
2004-01-01
Project End
2008-12-31
Budget Start
2006-01-01
Budget End
2006-12-31
Support Year
3
Fiscal Year
2006
Total Cost
$459,097
Indirect Cost
Name
University of Pennsylvania
Department
Psychiatry
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Jung, Jeesun; Tawa, Elisabeth A; Muench, Christine et al. (2017) Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res 254:8-11
Saung, Wint Thu; Narasimhan, Sneha; Lohoff, Falk W (2014) Lack of influence of DAT1 and DRD2 gene variants on antidepressant response in generalized anxiety disorder. Hum Psychopharmacol 29:316-21
Lohoff, F W; Narasimhan, S; Rickels, K (2013) Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J 13:464-9
Cooper, Alissa J; Narasimhan, Sneha; Rickels, Karl et al. (2013) Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res 210:1299-300
Lohoff, F W; Aquino, T D; Narasimhan, S et al. (2013) Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J 13:21-6
Rickels, Karl; Etemad, Bijan; Rynn, Moira A et al. (2013) Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR. Psychother Psychosom 82:363-71
Cooper, Alissa J; Rickels, Karl; Lohoff, Falk W (2013) Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder. Hum Psychopharmacol 28:258-62
Narasimhan, Sneha; Aquino, Tiffany D; Multani, Pushpinder K et al. (2012) Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res 198:112-5
Narasimhan, Sneha; Aquino, Tiffany D; Hodge, Rachel et al. (2011) Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Neurosci Lett 503:200-2
Narasimhan, Sneha; Hodge, Rachel; Doyle, Glenn A et al. (2011) Association analysis between the 5-HTTLPR polymorphism in the SLC6A4 gene and generalized anxiety disorder. Psychiatr Genet 21:267-8

Showing the most recent 10 out of 13 publications